Clinical trial
Immunogenicity and Safety Study of GSK Biologicals' Boostrix™ Vaccine Using a New Syringe Presentation in Healthy Adolescents Aged 10-15 Years
NCT01362322 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety Study of GSK Biologicals' Boostrix™ Vaccine Using a New Syringe Presentation in Healthy Adolescents Aged 10-15 Years
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 1, 2011
- Completion date
- September 3, 2012
- Enrollment
- 671 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
acellular pertussis, diphtheria, tetanus